Literature DB >> 12766067

Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis.

Wolfram Schreiber1, Antje Olbrisch, Christian K Vorwerk, Wolfgang König, Wolfgang Behrens-Baumann.   

Abstract

PURPOSE: To determine the most efficient time point and concentration of topical corticosteroids in Candida albicans keratitis treated with fluconazole.
METHODS: Corneas of 105 rabbits were infected with viable yeast cells of C. albicans (2.5 x 10(5)). After a 48-hour incubation period, seven groups of animals were treated for 21 days with fluconazole, with group I acting as a control, and groups II to VII receiving adjunct therapy with the corticosteroid prednisolone (5 or 10 times daily; 3, 9, or 15 days after infection). The degree of corneal infiltration, ulceration, corneal clouding, hypopyon, conjunctivitis, neovascularization, and corneal perforation was monitored over a 24-day period, as well as recultivation and resistance to fluconazole of the C. albicans pathogen.
RESULTS: The control group showed the highest level of corneal clouding and neovascularization. In comparison, by day 24, the majority of groups also treated with prednisolone displayed significantly less corneal clouding and neovascularization. An immediate decrease in corneal clouding was observed in groups treated with additional low- or high-dose prednisolone from day 9 after inoculation. After additional prednisolone treatment from day 9 or 15 after inoculation, no significant difference was detected in the recultivation rate of C. albicans compared with the control. Early administration of prednisolone (day 3, low and high dose) resulted in the recultivation of significantly more C. albicans.
CONCLUSIONS: Fluconazole plus adjunct high-dose prednisolone treatment was most effective when administered 9 days after infection. The delayed application of corticosteroids after treatment with antimycotic drugs in cases of fungal keratitis is therefore not contraindicated and may be beneficial in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766067     DOI: 10.1167/iovs.02-1135

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  The role of corticosteroids in fungal keratitis: a different view.

Authors:  V Peponis; J B Herz; H E Kaufman
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

2.  [The German Acanthamoeba keratitis register: Initial results of a multicenter study].

Authors:  L Daas; N Szentmáry; T Eppig; A Langenbucher; A Hasenfus; M Roth; M Saeger; B Nölle; B Lippmann; D Böhringer; T Reinhard; C Kelbsch; E Messmer; U Pleyer; S Roters; A Zhivov; K Engelmann; J Schrecker; L Zumhagen; H Thieme; R Darawsha; T Meyer-Ter-Vehn; B Dick; I Görsch; M Hermel; M Kohlhaas; B Seitz
Journal:  Ophthalmologe       Date:  2015-09       Impact factor: 1.059

3.  Effect of itraconazole on the cornea in a murine suture model and penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Eun Young Shin; Hironori Uehara; Balamurali Ambati
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

Review 4.  [Therapy and prognosis of bacterial keratitis].

Authors:  W Behrens-Baumann; U Pleyer
Journal:  Ophthalmologe       Date:  2007-01       Impact factor: 1.059

5.  [Adjunctive corticosteroids for antimicrobial treatment].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2016-11       Impact factor: 1.059

6.  Efficacy and safety of extemporaneously prepared miconazole eye drops in Candida albicans-induced keratomycosis.

Authors:  Linda Gyanfosu; George Asumeng Koffuor; Samuel Kyei; Ben Ababio-Danso; Kwabena Peprah-Donkor; Wilson Bright Nyansah; Frederick Asare
Journal:  Int Ophthalmol       Date:  2017-09-12       Impact factor: 2.031

Review 7.  [Keratomycosis: diagnosis and therapy].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

8.  Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis.

Authors:  Güliz Fatma Yavas; Faruk Oztürk; Tuncay Küsbeci; Zafer Cetinkaya; Sitki Samet Ermis; Nuri Kiraz; Umit Ubeyt Inan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-02       Impact factor: 3.117

9.  Evaluation of Liposomal and Conventional Amphotericin B in Experimental Fungal Keratitis Rabbit Model.

Authors:  Anup Kumar Ghosh; Shivaprakash Mandya Rudramurthy; Amit Gupta; Hansraj Choudhary; Shreya Singh; Anchal Thakur; Manu Jatana
Journal:  Transl Vis Sci Technol       Date:  2019-06-06       Impact factor: 3.283

10.  Corneal neovascularization during experimental fungal keratitis.

Authors:  Xiaoyong Yuan; Kirk R Wilhelmus
Journal:  Mol Vis       Date:  2009-09-29       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.